Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer

Int J Gynecol Cancer. 2017 Sep;27(7):1343-1349. doi: 10.1097/IGC.0000000000001037.

Abstract

Objective: This study aimed to evaluate the prognosis significance of zinc-finger E-box binding homeobox 2 (ZEB2) and transforming growth factor β1 (TGF-β1) as well as other clinical characteristics in epithelial ovarian cancer (EOC).

Methods: This retrospective study examined the expressions of ZEB2 and TGF-β1 in 64 EOC specimens, 36 benign ovarian tumor specimens, and 28 normal ovarian specimens by immunohistochemistry. The correlation of the expressions of ZEB2 and TGF-β1 was analyzed by the Spearman rank correlation analysis. The Kaplan-Meier method was used to construct crude survival curves, and the prognostic roles of ZEB2 and TGF-β1 as well as clinical characteristics were evaluated by Cox proportional hazards regression analysis.

Results: The positive expression rates of ZEB2 and TGF-β1 were increased in EOC specimens compared with benign ovarian tumor and normal ovary specimens (P < 0.05), and ZEB2 expression was positively correlated with TGF-β1 expression (r = 0.538, P = 0.000). In addition, the overall survival rate of EOC patients was associated with the expressions of ZEB2 and TGF-β1, age, differentiated grade, International Federation of Gynecology and Obstetrics (FIGO) stage, preoperative serum CA125 level, postoperative start time of chemotherapy, and treatment course (all P < 0.05). Multivariate Cox regression demonstrated that FIGO stage (P = 0.033), TGF-β1 expression (P = 0.043), postoperative start time of chemotherapy (P = 0.009), and treatment course (P = 0.000) were prognostic factors for EOC.

Conclusions: ZEB2 and TGF-β1 may promote EOC progression, and FIGO stage, TGF-β1 expression, postoperative start time of chemotherapy, and treatment course may be associated with the prognosis of EOC.

Keywords: EMT - epithelial mesenchymal transition; Epithelial ovarian cancer; FIGO - International Federation of Gynecology and Obstetrics; Prognostic factors; TGF-β1 - transforming growth factor β1; Transforming growth factor β1; ZEB2 - zinc-finger E-box binding homeobox 2; Zinc-finger E-box binding homeobox 2.

MeSH terms

  • Biomarkers, Tumor / biosynthesis*
  • Carcinoma, Ovarian Epithelial / metabolism*
  • Carcinoma, Ovarian Epithelial / pathology
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Survival Rate
  • Transforming Growth Factor beta1 / biosynthesis*
  • Zinc Finger E-box Binding Homeobox 2 / biosynthesis*

Substances

  • Biomarkers, Tumor
  • Transforming Growth Factor beta1
  • ZEB2 protein, human
  • Zinc Finger E-box Binding Homeobox 2